This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McEwan, D. G. Articles by Frame, M. C. Search for Related Content PubMed PubMed Citation Articles by McEwan, D. G. Articles by Frame, M. C.

Chemoresistant KM12C Colon Cancer Cells Are Addicted to Low Cyclic AMP Levels in a Phosphodiesterase 4–Regulated Compartment via Effects on Phosphoinositide 3-Kinase

¹ The Beatson Institute for Cancer Research, Cancer Research UK Beatson Laboratories; ² Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, IBLS, University of Glasgow, Glasgow, United Kingdom; and ³ Division of Molecular Physiology, College of Life Sciences, Wellcome Trust Biocentre, University of Dundee, Dundee, United Kingdom

Requests for reprints: Margaret C. Frame, The Beatson Institute for Cancer Research, Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, United Kingdom. Phone: 44-141-330-3953; Fax: 44-141-942-6521; E-mail: m.frame{at}beatson.gla.ac.uk.

One of the major problems in treating colon cancer is chemoresistance to cytotoxic chemotherapeutic agents. There is therefore a need to devise new strategies to inhibit colon cancer cell growth and survival. Here, we show that a combination of low doses of the adenylyl cyclase activator forskolin together with the specific cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) inhibitor rolipram, but not the cAMP phosphodiesterase-3 (PDE3) inhibitor cilostamide, causes profound growth arrest of chemoresistant KM12C colon cancer cells. Low-dose forskolin causes KM12C cells to exit the cell cycle in G₁ by inducing p27^Kip1 and primes cells for apoptosis on addition of rolipram. The effect of the low-dose forskolin/rolipram combination is mediated by displacement of the phosphatidylinositol 3,4,5-trisphosphate/phosphoinositide 3-kinase signaling module from the plasma membrane and suppression of the Akt/protein kinase-B oncogene pathway, to which KM12C cells are addicted for growth. The cAMP and phosphoinositide 3-kinase pathways form a critical intersection in this response, and reexpression of the tumor suppressor lipid phosphatase, phosphatase and tensin homologue, which is commonly lost or mutated in colon cancer, sensitizes KM12C cells to growth inhibition by challenge with low-dose forskolin. Certain chemoresistant colon cancer cells are therefore exquisitely sensitive to subtle elevation of cAMP by a synergistic low-dose adenylyl cyclase activator/PDE4 inhibitor combination. Indeed, these cells are addicted to maintenance of low cAMP concentrations in a compartment that is regulated by PDE4. Well-tolerated doses of PDE4 inhibitors that are already in clinical development for other therapeutic indications may provide an exciting new strategy for the treatment of colon cancer. [Cancer Res 2007;67(11):5248–57]

This article has been cited by other articles:

				P. Goldhoff, N. M. Warrington, D. D. Limbrick Jr., A. Hope, B. M. Woerner, E. Jackson, A. Perry, D. Piwnica-Worms, and J. B. Rubin Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor Regression Clin. Cancer Res., December 1, 2008; 14(23): 7717 - 7725. [Abstract] [Full Text] [PDF]